Al­ny­lam files a new set of law­suits against Mod­er­na and Pfiz­er over Covid-19 vac­cines

Al­ny­lam has once again ac­cused Pfiz­er and Mod­er­na of in­fring­ing patents around its lipid nanopar­ti­cle tech­nol­o­gy.

In two law­suits filed Fri­day, Al­ny­lam al­leged that Pfiz­er and Mod­er­na ben­e­fit­ed from the lipid par­ti­cle tech­nol­o­gy it in­vent­ed more than a decade ago. Al­so known as LNPs, the par­ti­cles pro­tect mR­NA mol­e­cules once ad­min­is­tered in­side the body, and al­so help es­cort it across cell mem­branes. Once in­side a cell, they un­pack mR­NA’s es­sen­tial pro­tein-build­ing in­struc­tions to cre­ate, for ex­am­ple, spike pro­teins to prime the im­mune sys­tem against Covid-19.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER